Immunologic constant of rejection as a predictive biomarker of immune checkpoint inhibitors efficacy in non-small cell lung cancer.
Alice MogenetPascal FinettiEmilie DenicolaiLaurent GreillierPascaline Boudou-RouquetteFrançois GoldwasserGwenael LumetMichele CeccarelliDaniel BirnbaumDavide BedognettiEmilie MamessierFabrice BarlesiFrançois BertucciPascale TomasiniPublished in: Journal of translational medicine (2023)
The 20-gene ICR signature was independently associated with benefit from anti-PD1/PDL1 ICI in patients with advanced NSCLC. Validation in larger retrospective and prospective series is warranted.